Goldstone Financial Group LLC Acquires Shares of 16,409 Pfizer Inc. (NYSE:PFE)

Goldstone Financial Group LLC purchased a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 16,409 shares of the biopharmaceutical company's stock, valued at approximately $416,000.

A number of other hedge funds also recently bought and sold shares of the business. Kelly Financial Group LLC bought a new stake in shares of Pfizer in the 1st quarter worth approximately $441,000. RTD Financial Advisors Inc. boosted its position in shares of Pfizer by 1.2% in the 1st quarter. RTD Financial Advisors Inc. now owns 52,692 shares of the biopharmaceutical company's stock worth $1,335,000 after purchasing an additional 636 shares in the last quarter. Elevation Point Wealth Partners LLC boosted its position in shares of Pfizer by 15.9% in the 1st quarter. Elevation Point Wealth Partners LLC now owns 16,809 shares of the biopharmaceutical company's stock worth $426,000 after purchasing an additional 2,311 shares in the last quarter. Krilogy Financial LLC boosted its position in shares of Pfizer by 9.0% in the 1st quarter. Krilogy Financial LLC now owns 50,630 shares of the biopharmaceutical company's stock worth $1,283,000 after purchasing an additional 4,196 shares in the last quarter. Finally, Everhart Financial Group Inc. boosted its position in shares of Pfizer by 29.9% in the 1st quarter. Everhart Financial Group Inc. now owns 14,528 shares of the biopharmaceutical company's stock worth $368,000 after purchasing an additional 3,347 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Down 1.3%

Shares of PFE stock traded down $0.33 during trading hours on Friday, reaching $24.51. 46,354,360 shares of the company's stock were exchanged, compared to its average volume of 41,209,115. The stock's 50 day moving average is $23.06 and its 200-day moving average is $24.95. The company has a market cap of $139.35 billion, a price-to-earnings ratio of 17.38, a P/E/G ratio of 0.64 and a beta of 0.57. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same period in the prior year, the company earned $0.82 earnings per share. The firm's revenue was down 7.8% on a year-over-year basis. Analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, June 13th. Investors of record on Friday, May 9th were given a dividend of $0.43 per share. The ex-dividend date was Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.02%. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Cantor Fitzgerald assumed coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective on the stock. The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Citigroup reissued a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Finally, UBS Group increased their price target on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.